Clinical impact of gastrectomy for gastric cancer patients with positive lavage cytology without gross peritoneal dissemination

2022 ◽  
Author(s):  
Hiroshi Kobayashi ◽  
Michitaka Honda ◽  
Hidetaka Kawamura ◽  
Koichi Takiguchi ◽  
Atsushi Muto ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Peritoneal Dissemination ◽  
Clinical Impact ◽  
Lavage Cytology ◽  
Gastric Cancer Patients

scholarly journals Intraoperative peritoneal lavage cytology offers prognostic significance for gastric cancer patients with curative resection

2017 ◽  
Vol 108 (5) ◽  
pp. 978-986 ◽  
Author(s):  
Eiji Higaki ◽  
Shinya Yanagi ◽  
Naoto Gotohda ◽  
Takahiro Kinoshita ◽  
Takeshi Kuwata ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Curative Resection ◽  
Peritoneal Lavage ◽  
Prognostic Significance ◽  
Peritoneal Lavage Cytology ◽  
Lavage Cytology ◽  
Gastric Cancer Patients

Surgical resection with hyperthermic intraperitoneal chemotherapy for gastric cancer patients with peritoneal dissemination

2010 ◽  
Vol 102 (5) ◽  
pp. 361-365 ◽  
Author(s):  
Chen Li ◽  
Min Yan ◽  
Jun Chen ◽  
Min Xiang ◽  
Zheng Gang Zhu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Surgical Resection ◽  
Intraperitoneal Chemotherapy ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Peritoneal Dissemination ◽  
Gastric Cancer Patients

Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients

2004 ◽  
Vol 88 (4) ◽  
pp. 240-247 ◽  
Author(s):  
Fabrizio Romano ◽  
Giovanni Cesana ◽  
Mattia Berselli ◽  
Maria Gaia Piacentini ◽  
Roberto Caprotti ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Clinical Impact ◽  
Gastric Cancer Patients

Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 4542-4542
Author(s):  
H. Ishigami ◽  
J. Kitayama ◽  
S. Kaisaki ◽  
A. Hidemura ◽  
M. Kato ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Peritoneal Metastasis ◽  
Response Rate ◽  
Peritoneal Dissemination ◽  
Phase Ii Study ◽  
Malignant Ascites ◽  
Peritoneal Cytology ◽  
Grade 3 ◽  
Gastric Cancer Patients

4542 Background: A phase II study to evaluate the efficacy and tolerability of weekly intravenous and intraperitoneal paclitaxel combined with S-1 was performed in gastric cancer patients with peritoneal metastasis. Methods: Gastric cancer patients with peritoneal dissemination and/or cancer cells on peritoneal cytology were enrolled. Paclitaxel was administered intravenously at 50 mg/m2 and intraperitoneally at 20 mg/m2 on days 1 and 8. S-1 was administered at 80 mg/m2/day for 14 consecutive days, followed by 7 days rest. The primary endpoint was the 1-year overall survival rate. Secondary endpoints were the response rate, efficacy against malignant ascites and safety. Results: Forty patients were enrolled, including 21 with primary tumors with peritoneal dissemination confirmed by staging laparoscopy, 13 with peritoneal recurrence, and 6 with positive peritoneal cytology only. The median number of courses administered was 7 (range 1–23). The 1-year overall survival rate was 78% (95% CI, 65–90%). The overall response rate was 56% (95% CI, 32–79%) in 18 patients with target lesions. Malignant ascites disappeared or decreased in 13 of 21 (62%) patients. The incidences of grade 3/4 hematological and non- hematological toxicities were 40% and 15%, respectively. The frequent grade 3/4 toxicities included neutropenia (38%), leukopenia (18%), anemia (10%), and nausea (8%). Catheter obstruction observed in one patient was the only complication related to the peritoneal access device or intraperitoneal infusion. There were no treatment-related deaths. Conclusions: Combination chemotherapy of intravenous and intraperitoneal paclitaxel with S-1 is well tolerated and active in gastric cancer patients with peritoneal metastasis. No significant financial relationships to disclose.

scholarly journals The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients

2018 ◽  
Vol 81 (7) ◽  
pp. 593-598 ◽  
Author(s):  
Yi-Ping Hung ◽  
Ming-Huang Chen ◽  
June-Seng Lin ◽  
Chin-Fu Hsiao ◽  
Yan-Shen Shan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Clinical Impact ◽  
The Novel ◽  
Unresectable Gastric Cancer ◽  
Gastric Cancer Patients

Clinical impact of aneuploidy on gastric cancer patients

2009 ◽  
Vol 11 (8) ◽  
pp. 493-498 ◽  
Author(s):  
Isabel Sánchez-Pérez ◽  
Pilar García Alonso ◽  
Cristóbal Belda Iniesta
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Clinical Impact ◽  
Gastric Cancer Patients

scholarly journals Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study

2001 ◽  
Vol 4 (4) ◽  
pp. 212-218 ◽  
Author(s):  
Makoto Tahara ◽  
Atsushi Ohtsu ◽  
Narikazu Boku ◽  
Fumio Nagashima ◽  
Manabu Muto ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Retrospective Study ◽  
Cancer Patients ◽  
Peritoneal Dissemination ◽  
Gastric Cancer Patients ◽  
Sequential Methotrexate

Long-term results and prognostic factors of gastric cancer patients with only positive peritoneal lavage cytology

2011 ◽  
Vol 105 (4) ◽  
pp. 393-399 ◽  
Author(s):  
Cheong Ah Oh ◽  
Jae Moon Bae ◽  
Seung Jong Oh ◽  
Min Gew Choi ◽  
Jae Hyung Noh ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Peritoneal Lavage ◽  
Long Term Results ◽  
Peritoneal Lavage Cytology ◽  
Lavage Cytology ◽  
Gastric Cancer Patients

scholarly journals Re: Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer Patients with Peritoneal Dissemination

2011 ◽  
Vol 18 (S3) ◽  
pp. 189-189
Author(s):  
Jung Ho Shim ◽  
Cho Hyun Park ◽  
Kyo Young Song
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Systemic Chemotherapy ◽  
Peritoneal Dissemination ◽  
Gastric Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document